Lexaria says its five-week trial testing DehydraTECH semaglutide tablets and capsules is fully enrolled, with the final group set to finish dosing in mid-November.
Recap by typeshit. Full story at Investing News Network.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
NYU's Holly Lofton and Harvard's Jennifer Manne-Goehler say trial safety looks similar to other GLP-1s, but warn gray market vials may hold no active drug.
A short PBS clip with a herpetologist on how GLP-1 medications trace back to a lizard.
Loading…